Global Lurasidone Hydrochloride Tablets Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Lurasidone Hydrochloride Tablets Market Research Report 2024
Lurasidone hydrochloride tablet is an antipsychotic drug that exerts a sedative effect through combined antagonism of central dopamine and serotonin receptors. Mainly used for the treatment of schizophrenia.
According to QYResearch’s new survey, global Lurasidone Hydrochloride Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Lurasidone Hydrochloride Tablets market research.
Key manufacturers engaged in the Lurasidone Hydrochloride Tablets industry include Sunovion, Bushu Pharma, Zhe JIANG HUA HAI Pharmaceutical Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd., Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd., YANGTZE River Pharmaceutical Group Nanjing Pharmaceutical. Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Co., Ltd., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Lurasidone Hydrochloride Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Lurasidone Hydrochloride Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Lurasidone Hydrochloride Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sunovion
Bushu Pharma
Zhe JIANG HUA HAI Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.
YANGTZE River Pharmaceutical Group Nanjing Pharmaceutical. Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Segment by Type
20mg(C₂₈H₃₆N₄O₂S·HCl)
40mg(C₂₈H₃₆N₄O₂S·HCl)
Hospital
Retail Pharmacy
Clinic
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Lurasidone Hydrochloride Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to QYResearch’s new survey, global Lurasidone Hydrochloride Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Lurasidone Hydrochloride Tablets market research.
Key manufacturers engaged in the Lurasidone Hydrochloride Tablets industry include Sunovion, Bushu Pharma, Zhe JIANG HUA HAI Pharmaceutical Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd., Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd., YANGTZE River Pharmaceutical Group Nanjing Pharmaceutical. Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Co., Ltd., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Lurasidone Hydrochloride Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Lurasidone Hydrochloride Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Lurasidone Hydrochloride Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sunovion
Bushu Pharma
Zhe JIANG HUA HAI Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.
YANGTZE River Pharmaceutical Group Nanjing Pharmaceutical. Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Segment by Type
20mg(C₂₈H₃₆N₄O₂S·HCl)
40mg(C₂₈H₃₆N₄O₂S·HCl)
Segment by Application
Hospital
Retail Pharmacy
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Lurasidone Hydrochloride Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source